BrightPath Biotherapeutics Co., Ltd. (4594) Other
Market cap
¥6.3B
P/E ratio
-5.2x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Return on Assets | - | - | - | - | -9.8 | -9.8 | -6.3 | -8.7 | -11.8 | -12.2 | -12.4 | -11.6 | -24.1 | -28.6 |
| Return on equity (%) | - | - | - | |||||||||||
| Employees | 12 | 11 | 16 | 19 | 21 | 37 | 42 | 42 | 44 | 44 | 38 | 32 | 24 | 24 |